Cargando…

Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours

BACKGROUND: Berzosertib (formerly M6620, VX-970) is a highly potent and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. We assessed the safety, tolerability, pharmacokinetics, and preliminary efficacy of berzosertib plus cisplatin. METHODS: Ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shapiro, Geoffrey I., Wesolowski, Robert, Devoe, Craig, Lord, Simon, Pollard, John, Hendriks, Bart S., Falk, Martin, Diaz-Padilla, Ivan, Plummer, Ruth, Yap, Timothy A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367944/ https://www.ncbi.nlm.nih.gov/pubmed/34040174 http://dx.doi.org/10.1038/s41416-021-01406-w

Ejemplares similares

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
por: Middleton, Mark R., et al.
Publicado: (2021)

Population pharmacokinetics of ATR inhibitor berzosertib in phase I studies for different cancer types
por: Terranova, Nadia, et al.
Publicado: (2020)

Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer
por: Telli, Melinda L., et al.
Publicado: (2022)

The ATR inhibitor berzosertib acts as a radio- and chemosensitizer in head and neck squamous cell carcinoma cell lines
por: Schnoell, Julia, et al.
Publicado: (2023)

Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
por: Liu, Chaofan, et al.
Publicado: (2023)

Berzosertib (VE-822) inhibits gastric cancer cell proliferation via base excision repair system
por: Ni, Fubiao, et al.
Publicado: (2019)

ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
por: Williamson, Chris T., et al.
Publicado: (2016)

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition
por: Pires, I M, et al.
Publicado: (2012)

Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors
por: Yap, Timothy A., et al.
Publicado: (2020)

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours
por: Plummer, R, et al.
Publicado: (2011)

ATR mediates cisplatin resistance in a p53 genotype-specific manner
por: Sangster-Guity, N, et al.
Publicado: (2011)

The ATR inhibitor VE-821 increases the sensitivity of gastric cancer cells to cisplatin
por: Su, Haochen, et al.
Publicado: (2023)

A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours
por: Diaz-Padilla, I, et al.
Publicado: (2012)

ATR inhibition enables complete tumour regression in ALK-driven NB mouse models
por: Szydzik, Joanna, et al.
Publicado: (2021)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

Response of peritoneal solid tumours after intraperitoneal chemohyperthermia treatment with cisplatin or carboplatin.
por: Los, G., et al.
Publicado: (1994)

Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA
por: Menolfi, Demis, et al.
Publicado: (2018)

ATR activation is regulated by dimerization of ATR activating proteins
por: Thada, Vaughn, et al.
Publicado: (2021)

Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells
por: Chen, Sansan, et al.
Publicado: (2016)

ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma
por: Zhang, Bo, et al.
Publicado: (2019)

Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: A retrospective evaluation
por: ASTOLFI, LAURA, et al.
Publicado: (2013)

The Impact of p53 Dysfunction in ATR Inhibitor Cytotoxicity and Chemo- and Radiosensitisation
por: Middleton, Fiona K., et al.
Publicado: (2018)

ATR-Chk1 signaling inhibition as a therapeutic strategy to enhance cisplatin chemosensitivity in urothelial bladder cancer
por: Li, Ching-Chia, et al.
Publicado: (2015)

VE-822 mediated inhibition of ATR signaling sensitizes chondrosarcoma to cisplatin via reversion of the DNA damage response
por: Liang, Xiao, et al.
Publicado: (2019)

IGF-1R inhibition sensitizes breast cancer cells to ATM-related kinase (ATR) inhibitor and cisplatin
por: O'Flanagan, Ciara H., et al.
Publicado: (2016)

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
por: Planting, A. S., et al.
Publicado: (1993)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Cell subpopulations dispersed from solid tumours and separated by centrifugal elutriation.
por: Siemann, D. W., et al.
Publicado: (1981)

Thé{circ}atre
por: Delavigne, Casimir, 1793-1843
Publicado: (1835)

Thé{circ}atre
por: Delavigne, Casimir, 1793-1843
Publicado: (1835)

Thé{circ}atre
por: Marivaux, Pierre Carlet de Chamblain de, 1688-1763
Publicado: (1959)

Pharmacological Inhibition of ATR Can Block Autophagy through an ATR-Independent Mechanism
por: Bowler, Elizabeth, et al.
Publicado: (2020)

ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation
por: Gomes, Luciana Rodrigues, et al.
Publicado: (2019)

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours
por: Ameratunga, Malaka, et al.
Publicado: (2020)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
por: du Bois, A, et al.
Publicado: (2006)

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours
por: Chen, X, et al.
Publicado: (2003)

The Role of Tumour Metabolism in Cisplatin Resistance
por: Wang, Lude, et al.
Publicado: (2021)

Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care
por: Cameron, James M., et al.
Publicado: (2020)

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours
por: Wilson, Richard H, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_o0aq74g5bh11neflb5upe8lor6